**Adherence, Compliance, and Persistence**

- Relationship of the magnitude of member cost-share and medication persistence with newly initiated renin angiotensin system blockers. 2007;13(8):664-76.
- Patient adherence with HMG reductase inhibitor therapy among users of two types of prescription services. 2002;8(3):186-91.
- Adherence, compliance, and persistence in drug therapy. 2002;8(3):177-78.
- Evaluating medication adherence: which measure is right for your program? 2000;6(6):499-504.

**Adverse Drug Events**

- Medical errors, adverse medical events, and PDRM. 2002;8(5):400.
- Evaluation of resources used to treat adverse events of selective serotonin reuptake inhibitor use. 2001;7(5):402-06.

**Behavioral Health**


**Biotechnology**


**Capitation and Risk-Financing Methods**


**Clinical Pharmacy—Patient Consultation**


Clinical Pharmacy—Payment for Services

• Mississippi Medicaid waiver breaks new ground for pharmacists. 1996;2(6):564, 566.

Clinical Pharmacy Interventions—Quality, Service, and Cost Outcomes

• Adherence to clinical practice guidelines for 7 chronic conditions in long-term-care patients who received pharmacist disease management services versus traditional drug regimen review. 2007;13(1):28-36.
• Experience with a clinical decision support system in community pharmacies to recommend narrow-spectrum antimicrobials, nonantimicrobial prescriptions, and OTC products to decrease broad-spectrum antimicrobial use. 2006;12(5):390-97.
• Assessment of patient satisfaction with telephone and mail interventions provided by a clinical pharmacy cardiac risk reduction service. 2005;11(5):403-09.
• Clinical pharmacist interventions to bridge the quality chasm and methods necessary to hold quality improvement gains. [editorial] 2004;10(2):167-68.
• Assessment of clinical pharmacist management of lipid-lowering therapy in a primary care setting. 2003;9(3):269-73.
• Determining the value of pharmacy services—the search for rigorous research designs. 2002;8(2):152-53.
• Factors affecting pharmacist consultation services in a university health insurance plan. 2002;8(1):55-56.

Clinical Pharmacy Quality Improvement—Patient Safety and Prevention of ADEs

• Integration of medical and pharmacy claims to better protect patient safety—a long road yet to travel. 2007;13(5):429-30.
• Telithromycin: the perils of hasty adoption and persistence of off-label prescribing. 2007;13(5):420-25
Clinical Practice Guidelines (CPGs) and Quality Improvement

- Liver and thyroid monitoring in ambulatory patients prescribed amiodarone in 10 HMOs. 2006;12(8):656-64.

Clinical Quality Improvement

- Framework for pharmacy services quality improvement—a bridge to cross the quality chasm. 2004;10(1):60-78.
- Managing drug therapy decisions: pay me now or pay me later. 1998;4(3):242, 245.

Collaboration—Pharmacists and Others

- Pharmacy practice in the long-term care environment. 1997;3(2):189-94.

Collaboration—Pharmacy Education

- Oregon State University partners with Medicaid and a managed care organization. 2001;7(3):185-86.
- The University of Colorado School of Pharmacy and the University of Colorado Health Plan forge a PBM partnership. 1998;4(5):478, 480.

Collaborative Practice—Pharmacists as Prescribers


Database Analyses of Drug Utilization (see also Research Methods and Statistical Analysis)

• Claims data and drawing appropriate conclusions. 2002;8(2):152.
• Basics of managed care claims processing: from claims payment to outcomes management. 1995;1(3):200-05.

**Decision Support Systems (DSS)**


**Direct-to-Consumer Advertising (DTCA)**

(see also Drug Promotion and Advertising)

• United States, the last venue for direct-to-consumer advertising, props up the erectile dysfunction market. [editorial] 2005;11(2):176-78.
• Direct-to-patient advertising (DTPA) and direct-to-consumer advertising (DTCA) of prescription drugs. 2002;8(6):521.
• Responding to direct-to-consumer advertising. 2000;6(3):201-02.
• Direct-to-consumer advertising provides challenge to managed care. 1999;5(2):101-03, 106.

**Disease Management—Airway Disease or Allergic Rhinitis**

• Quality of drug treatment of childhood persistent asthma in Maryland Medicaid recipients in transition from managed fee for service to managed capitation. 2007;13(4):310-18.
• Effects on resource utilization of adding salmeterol in combination or separately to inhaled corticosteroids. 2007;13(1):21-27.
• Health care utilization determined from administrative claims analysis for patients who received inhaled corticosteroids with either montelukast or salmeterol. [letter] 2006;12(6):486-87.
• More evolution of the evidence in asthma disease management—SMART versus GOAL clinical trials debate the cost-benefit of LABA while the value of leukotriene modifiers, particularly montelukast, is uncertain. [editorial] 2006;12(4):343-46.
• Administrative claims analysis of asthma-related health care utilization for patients who received inhaled corticosteroids with either montelukast or salmeterol as combination therapy. 2006;12(4):310-21.
• Selectivity and specificity are the keys to cost-effective use of omalizumab for allergic asthma. [editorial] 2005;11(9):774-76.
• Evaluation of omalizumab from a health plan perspective. 2005;11(9):735-45.
• New concepts to improve health outcomes for patients with chronic obstructive pulmonary disease. [supplement] 2005;11(6, S-a):S1-S22.
• Pediatric asthma: improving management to reduce cost of care. 2004;10(2):130-41.
• Enhancing value-based decision-making: allergic rhinitis. [supplement] 2004;10(1, S-a):S1-S17.
• Optimizing clinical and economic outcomes in asthma management: individualizing drug therapy to address dual components of asthma. [supplement] 2002;8(5):S1-S25.
• Evaluating asthma medication use before and after an acute asthma-related event. 2001;7(4):303-08.

Disease Management—ALS (Amyotrophic Lateral Sclerosis)

Disease Management—Alzheimer’s Disease

Disease Management—Angina, ACS, CHD, and CHF
• Total first-year costs of acute coronary syndrome in a managed care setting. 2005;11(4):300-06.

Disease Management—Arthritis and Joint Pain
• Modernization versus limitation: cross-firing the impact of the AHRQ Effective Health Care Program on access to biologic therapies. [supplement] 2007;13(1):S1-S24.
• Review of eight pharmacoeconomic studies of the value of biologic (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis. 2006;12(7):555-69.
• COX-2 inhibitors: little or no GI protection, increased risk of cardiovascular events, high cost, and other class-less effects. [editorial] 2005;11(7):590-93.
• Gastrointestinal bleeding rates among managed care patients newly started on COX-2 inhibitors or nonselective NSAIDs. 2005;11(7):550-58.
• Relationship of clinical factors to the use of COX-2 selective NSAIDs within an arthritis population in a large HMO. 2002;8(4):252-58.
• Economic considerations in the management of arthritis. 1999;5(6):476-78, 481-82, 484.

Disease Management—Atopic Dermatitis
• Atopic march to a dead end or does the theory really have legs? [editorial] 2007;13(9):810-11.
• Economic burden of atopic manifestations in patients with atopic dermatitis—analysis of administrative claims. 2007;13(9):778-89.
• Administrative claims analysis of utilization and costs of care for atopic dermatitis—analysis of administrative claims. 2007;13(9):778-89.
• Modernization versus limitation: cross-firing the impact of the AHRQ Effective Health Care Program on access to biologic therapies. [supplement] 2007;13(1):S1-S24.
• Relationship of clinical factors to the use of COX-2 selective NSAIDs within an arthritis population in a large HMO. 2002;8(4):252-58.
• The effect of atopic dermatitis on total burden of illness and quality of life on adults and children in a large managed care organization. 2002;8(5):333-42.

Disease Management—Attention-Deficit/Hyperactivity Disorder (ADHD)
• Changes and challenges: managing ADHD in a fast-paced world. [supplement] 2007;13(9, S-b):S1-S16.
• ADD or ADHD or what exactly?—GIGO part II and other lessons in research with administrative claims. [editorial] 2007;13(7):617-19.
• Continuity in methylphenidate treatment of adults with attention-deficit/hyperactivity disorder. 2007;13(7):570-77.
• Health care costs of adults treated for attention-deficit/hyperactivity disorder who received alternative drug therapies. 2007;13(7):561-69.
• Physician perceptions of the use of medications for attention deficit hyperactivity disorder. 2003;9(5):416-23.

**Disease Management—Benign Prostatic Hyperplasia**


**Disease Management—Cancer**

• Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3-4 week chemotherapy regimens in community oncology practices. 2007;13(4):337-48.
• Pharmacy benefit spending on oral chemotherapy drugs. 2006;12(7):570-77.

**Disease Management—Depression or Bipolar Disorder**

• Shrinking health care disparities in women: the depression dilemma. [supplement] 2007;13(9, S-a):S1-S36.
• Higher costs and therapeutic factors associated with adherence to NCQA HEDIS antidepressant medication management measures: analysis of administrative claims. 2006;12(1):43-54.
• Comparison of mental health resources used by patients with bipolar disorder treated with risperidone, olanzapine, or quetiapine. 2005;11(3):220-30.
• Depression in corporate America: an integrated care approach to increase productivity and improve outcomes. [supplement] 2005;11(2):172-76.
• Relationship of total health care charges to selective serotonin reuptake inhibitor utilization patterns including the length of antidepressant therapy—results from a managed care administrative claims database. 2005;11(2):145-50.
• Documentation of indicators for antidepressant treatment and response in an HMO primary care population. 2000;6(6):494-98.
• Utilization patterns of antidepressant medications in a patient population served by a primary care medical group. 1999;5(3):243-49.

**Disease Management—Diabetes (see also Clinical Pharmacy Interventions—Quality, Service, and Cost Outcomes)**

• Type 2 diabetes and cardiovascular disease: reducing the risk. [supplement] 2007;13(2, S-a):S1-S17.
- Total and component health care costs in a non-Medicare HMO population of patients with and without type 2 diabetes and with and without macrovascular disease. 2006;12(7):548-54.
- What are incretins, and how will they influence the management of type 2 diabetes? [supplement] 2006;12(7, S-a):S1-S16.
- Relationship of oral antihyperglycemic (sulfonylurea or metformin) medication adherence and hemoglobin A1c goal attainment for HMO patients enrolled in a diabetes disease management program. 2006;12(6):466-71.
- Blood pressure goal attainment according to JNC 7 guidelines and utilization of antihypertensive drug therapy in MCO patients with type 1 or type 2 diabetes. 2006;12(4):303-09.
- Utilization and costs for compliant patients initiating therapy with pioglitazone or rosiglitazone versus insulin in a Medicaid fee-for-service population. 2006;12(2):121-29.
- Relationship of glycemic control to total diabetes-related costs for managed care health plan members with type 2 diabetes. 2005;11(7):559-64.

**Disease Management—Dyslipidemia**

- LDL-C goal attainment among patients newly diagnosed with coronary heart disease or diabetes in a commercial HMO. 2007;13(8):652-63.
- Results of retrospective chart review to determine improvement in lipid goal attainment in patients treated by high-volume prescribers of lipid-modifying drugs. 2006;12(9):745-51.
- Lipid levels and use of lipid-lowering drugs for patients in pharmacist-managed lipid clinics versus usual care in 2 VA medical centers. 2005;11(9):763-71.
- Clinical and economic outcomes of conversion of simvastatin to lovastatin in a group-model health maintenance organization. 2005;11(8):681-86.
- Fish oil for heart disease—happy to be in second place. [editorial] 2005;11(7):584-85.
- Similar medication compliance and control of dyslipidemia with simvastatin or atorvastatin in a staff-model HMO medical clinic. 2005;11(6):499-504.
- Quantifying the effect of applying the NCEP ATP III criteria in a managed care population treated with statin therapy. 2004;10(3):244-50.
• Effective cholesterol management with fewer dollars. 2002;8(6):519.
• High blood cholesterol and ATPIII: guidelines for health benefit and health care providers. 2001;7(6):482-89.

Disease Management—Heartburn

• Employers need to have a wider horizon than drug costs alone when considering the implementation of health care intervention programs. [letter and author response] 2006;12(7):581-83.
• PPIs are therapeutically interchangeable and ideal for a managed care intervention such as therapeutic MAC. [editorial] 2006;12(7):578-80.
• Peptic acid disorders: developing a disease management program. 1996;2(3):569-75.

Disease Management—Hypertension and Cardiovascular Disease

• Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. 2006;12(3):239-45.
• Health care resources and costs for treating peripheral artery disease in a managed care population: results from analysis of administrative claims data. 2005;11(9):727-34.
• A literature review of cardiovascular disease management programs in managed care populations. 2004;10(4):326-44.
• Antihypertensive drug effects on renal function and myocardial infarction and implications of the ALLHAT study results. 2003;9(1):93-95.
• Impact of the ALLHAT study results on managed care. 2003;9(1):84-86.
• Risk of myocardial infarction with combination antihypertensive regimens including a dihydropyridine calcium channel blocker in hypertensive diabetics. 2003;9(1):29-35.

Disease Management—Irritable Bowel Syndrome


**Disease Management—Kidney Disease**

• Assessment of time and practice resources required to provide weekly or monthly erythropoiesis-stimulating protein therapy to chronic kidney disease patients in the physician office setting. 2006;12(9):714-25.

**Disease Management—Migraine Syndrome**

• Assessment of clinical, service, and cost outcomes of a conversion program of sumatriptan to rizatriptan ODT in primary care patients with migraine headaches. 2006; 12(3):246-53.
• Which is more elusive, the pot of gold at the end of a rainbow or determining the most cost-effective triptan? [editorial] 2005;11(6):513-15.
• Triptans for migraine therapy: a comparison based on number needed to treat and doses needed to treat. 2005; 11(5):394-402.
• Which triptan?—Opportunity for same or better outcomes at lower cost. [editorial] 2004;10(3):266.
• Meta-analysis of oral triptan therapy for migraine: number needed to treat and relative cost to achieve relief within 2 hours. 2003;9(1):43-52.

**Disease Management—Multiple Sclerosis**

• Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database. 2007;13(1):44-52.

**Disease Management—Obesity**

• The role of pharmaceuticals in reducing cardiometabolic risk: rethinking pharmacy benefit design to reduce the burden on the health care system. [supplement] 2006;12(1):S1-S16.
• “U Can’t Touch This” with pharmacotherapy alone for weight loss or smoking cessation. [editorial] 2005;11(6):516-20.
• Cost-effectiveness of sibutramine in theLOSE Weight Study: evaluating the role of pharmacologic weight-loss therapy within a weight management program. 2005;11(6):458-68.
• A cost-effective analysis of appetite suppressants for obesity treatment in a managed care organization. 1998;4(3):293-300.

**Disease Management—Osteoporosis**

• Comparison of risedronate to alendronate and calcitonin for early reduction of nonvertebral fracture risk: results from a managed care administrative claims database. 2004; 10(2):142-51.
• ERT, HRT, raloxifene, calcitonin, or bisphosphonates for osteoporosis. 2003;9(2):178-181.
• The cost of treating osteoporosis in a managed health care organization. 2003;9(2):142-49.

Disease Management—Otitis Media and Infectious Disease
• Fluoroquinolone-use evaluation by acute cystitis. 1996;2(5):564-68.

Disease Management—Psoriasis
• Step therapy is not appropriate for antiepileptic drugs. [letter] 2006;12(3):269-70.

Disease Management—Seizure Disorders and Epilepsy
• Disease Management—Thrombosis, DVT, and VTE
  • Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations. 2007;13(6):475-86.
  • Effect of a clinical pharmacy education program on improvement in the quantity and quality of venous thromboembolism prophylaxis for medically ill patients. 2005;11(9):755-62.
  • In search of safe and effective oral anticoagulation. [editorial] 2005;11(8):704-08.
  • Longitudinal evaluation of health plan cost per venous thromboembolism or bleed event in patients with a prior venous thromboembolism event during hospitalization. 2005;11(8):663-73.

Disease Management—Ulcerative Colitis
• Mild-to-moderate ulcerative colitis: your role in patient compliance and health care costs. [supplement] 2007;13(7, S-a):S1-S16.

Disease Pathology and Prevention

Dose Optimization
• Initial results of the use of prescription order change forms to achieve dose form optimization (consolidation and tablet splitting) of SSRI antidepressants in a state Medicaid program. 2006;12(6):449-56.
• Dose consolidation can be an efficient intervention. And author Response. [letters] 2004;10(6):564-66.
• Randomized controlled trial of a dose consolidation program. 2004;10(5):396-403.
• Dose-optimization intervention yields significant drug cost savings. 2002;8(2):146-51.
• Dose optimization: an opportunity for pharmacy administrative services. 2002;8(2):81.

Drug Benefit Management—Benchmarks and Measures
• Principles and practical applications of benchmarking. [supplement] 2005;11(1, S-a):S1-S23.
• Other DACON observations—community pharmacists do not intentionally transmit incorrect claim information—but caution is warranted in days supply calculations. [letter] 2004;10(2):174-75.
• Need for greater scrutiny of days supply values in DACON calculations. [letter] 2004;10(2):172-73.
• Searching for drug benefit benchmarks—cost per day of therapy. 2002;8(1):54-55.

**Drug Benefit Management—Benefit Design**

• Effect on drug utilization and expenditures of a cost-share change from copayment to coinsurance. 2007;13(9):765-77.
• Factors associated with choice of pharmacy setting among DoD health care beneficiaries aged 65 years or older. 2007;13(8):677-86.
• The elephant in the pharmacy: patient choice is the big challenge that no one talks about in affordability of prescription drugs. [editorial] 2007;13(7):620-22.
• Comparison of mail-order with community pharmacy in plan sponsor cost and member cost in two large pharmacy benefit plans. 2007;13(2):122-34.
• Relationship of the use and costs of physician office visits and prescription drugs to travel distance and increases in member cost share. 2006;12(8):665-76.
• Cost reduction strategies used by elderly patients with chronic obstructive pulmonary disease to cope with a generic-only pharmacy benefit. 2006;12(5):377-82.
• The estimated impact of drug importation, mandatory mail service, and Medicaid fee reduction on community pharmacies in Michigan. 2006;12(2):157-63.
• A 30-month evaluation of the effects on cost and utilization of proton pump inhibitors from adding omeprazole OTC to drug benefit coverage in a state employee health plan. 2006;12(1):25-32.

• The role of pharmaceuticals in reducing cardiometabolic risk: rethinking pharmacy benefit design to reduce the burden on the health care system. [supplement] 2006;12(1):S1-S16.
• Effects on the cost and utilization of proton pump inhibitors from adding over-the-counter omeprazole to drug benefit coverage in a state employee health plan. 2004;10(5):449-55.
• Does member cost-sharing pose a threat to desirable patient outcomes? 2004;10(3):256.
• 3-tier drug benefit designs based on sound drug formulary principles will maximize favorable outcomes. [editorial] 2004;10(1):83-84.
• Benefit maximums versus drug benefit needs for Medicare beneficiaries. 2002;8(5):402-03.
• Prescription use behavior among Medicare beneficiaries with capped prescription benefits. 2002;8(5):360-64.

**Drug Benefit Management—Efficiency and Patient Safety**

• Weight uniformity of split tablets required by a Veterans Affairs policy. 2003;9(5):401-07.
• Mail-order prescriptions requiring clarification contact with the prescriber: prevalence, reasons, and implications. 2003;9(4):346-52.
• Tablet splitting to improve the value-for-money equation in cholesterol management. 2002;8(6):519.
• A model to estimate drug plan cost savings from a trial prescription program. 2001;7(5):391-401.
• Pharmacy benefit administration options. 1996;2(3):272-78.

Drug Benefit Management—Employee Benefits and Coverage (see also Drug Benefit Management—Benefit Design)

• Member satisfaction related to self-reported cost share and difficulty in obtaining prescription drugs in a university pharmacy benefit plan. 2007;13(2):135-41.
• Older adults’ drug benefit beliefs: a focus group study. 2005;11(1):77-85.
• Anticipating the future: how the emergence of innovative biologic agents impacts benefit design, utilization, and provider relations. [supplement] 2004;10(3, S-a):S1-S20.
• New generic and OTC drugs provide opportunities for drug benefit managers. 2002;8(6):520.
• Analysis of the movement of prescription drugs to over-the-counter status. 2002;8(6):499-508.
• Employer-sponsored health care services. 2001;7(3):189-92.
• Successful disease management programs for health and welfare fund union groups. 1998;4(3):269-70, 272.

Drug Benefit Management—Patient Satisfaction, Benefit Knowledge, and Consumer Behavior

• Unraveling the effects of tier-copayment drug benefit designs. 2003;9(2):177-78.
• Effects of a 3-tier pharmacy benefit design on the prescription purchasing behavior of individuals with chronic disease. 2003;9(2):123-33.
• Consumer preferences for types of cost containment in prescription drug programs. 2002;8(3):192-98.
• Drugs, PPOs, tiered cost-share for beneficiaries, and consumer preferences. 2002;8(3):177.
• Patient satisfaction with and knowledge of their prescription drug coverage. 2001;7(1):34-42.
• A comparison of satisfaction with mail versus traditional pharmacy services. 1997;3(3):327-37.

Drug Benefit Management—Pharmacy Providers


Drug Benefit Management—Quantity Limits, Step Therapy, Prior Authorization (PA), Drug Pricing and Rebates

• Perceptions of Saskatchewan community pharmacists regarding a prior-authorization program. 2007;13(7):589-97.
• Effects of a physician office generic drug sampling system on generic dispensing ratios and drug costs in a large managed care organization. 2007;13(5):412-19.
• Effects of a step-therapy program for angiotensin receptor blockers on antihypertensive medication utilization patterns and cost of drug therapy. 2007;13(3):235-44.
• Utilization and cost of sildenafil in a large managed care organization with a quantity limit on sildenafil. 2005;11(8):674-80.
• The Academy of Managed Care Pharmacy's Concepts in Managed Care Pharmacy: prior authorization and the formulary exception process. [letter] 2005;11(4):358-61.
• Step-therapy edits for PPIs and COX-2 drugs—what we do and do not know. [editorial] 2004;10(4):356.
• Evaluation of a monthly coverage maximum (drug specific quantity limit) on the 5-HT1 agonists (triptans) and dihydroergotamine nasal spray. 2003;9(4):335-45.
• Prior authorization to manage drug utilization and costs. 2003;9(1):95.
• Analysis of a prescription drug prior authorization program in a Medicaid health maintenance organization. 2003;9(1):36-44.
• A neurologist’s perspective on quantity limits. 2002;8(3):184.
• Triptan quantity limits. 2002;8(3):182-84.
• Medical and pharmacy cost and utilization outcomes of a quantity limit on 5-HT1 agonists (triptans) by a managed care organization. 2001;7(6):468-75.

**Drug Promotion and Advertising (see also Direct-to-Consumer Advertising [DTCA])**

- Information requirements of health systems as drug purchasers: does the FDA have a role in setting evidentiary standards? 1998;4(6):593-98.

**Drug Spending, Utilization, and Cost Trends**

- Too much or too little? The role of pharmaceuticals in the health care system. 1999;5(4):296-97, 301-02.
- Local area market dynamics. 1998;4(2):115-17, 120.

**Drug Therapy—Natural Products**


**Drug Therapy, Therapeutic Selection, and P&T Decision Making**

- Pharmacist intervention in safe and effective conversion of brand to generic drugs. [letter] 2005;11(9):777.

Comparison of rates of potentially inappropriate medication use according to the Zhan criteria for VA versus private sector Veterans Affairs population using the HEDIS 2006 quality measure. 2006;12(7):537-45.


### Drug Utilization Review (DUR) or Drug Utilization Management—Appropriate Drug Use

- Examination of multiple medication use among TRICARE beneficiaries aged 65 years and older. 2007;13(2):155-62.
- Comparison of rates of potentially inappropriate medication use according to the Zhan criteria for VA versus private sector Medicare HMOs. 2006;12(5):362-70.
• Longitudinal analysis of the use of etanercept versus infliximab determined from medical chart audit. 2004;10(6):538-42.
• Frequency of simvastatin prescriptions with potentially interacting medications in a Veterans Affairs health care system. 2004;10(3):239-43.
• Gabapentin may be appropriate for off-label uses. [editorial] 2003;9(6):569-70.
• Examination of the evidence for off-label use of gabapentin. 2003;9(6):559-68.
• Analysis of medication use patterns: apparent overuse of antibiotics and underuse of prescription drugs for asthma, depression, and CHF. 2003;9(3):232-37.
• Gabapentin and indications of appropriate use. 2002;8(4):293-94.
• High frequency of itraconazole prescriptions with potentially interacting medications in a large health care plan. 2002;8(3):199-203.

Ethics

Formulary Management—Methods and Effects—Pharmacoeconomics
• Opinions regarding the Academy of Managed Care Pharmacy dossier submission guidelines: results of a small survey of managed care organizations and pharmaceutical manufacturers. 2007;13(4):360-71.
• P&T committees—black boxes versus AMCP Format, and what is the true cost and value of pimecrolimus. [editorial] 2005;11(1):93-94.
• The role of pharmacy benefit managers in formulary design: service providers or fiduciaries? [letter] 2004;10(4):359-60.
• Industry's perception of presenting pharmacoeconomic models to managed care organizations. 2003;9(2):159-67.
• Summary quality scores for pharmacoeconomic studies: balancing validity with need. 2003;9(1):87-88.
• Examining the value and quality of health economic analyses: implications of utilizing the QHES. 2003;9(1):53-61.
• Meta-analysis of oral triptan therapy for migraine: number needed to treat and relative cost to achieve relief within 2 hours. 2003;9(1):45-52.
• Exploring the methodological challenges of investigating comparison groups with different underlying characteristics: a case study. 2002;8(5):353-59.
• AMCP guidance for submission of clinical and economic evaluation data to support formulary listing in U.S. health plans and pharmacy benefits management organizations. 2001;7(4):272-82.
• The pros and cons of formularies. 2000;6(3):203-07.
• The role of pharmacoeconomic information in the formulary decision-making process. 2000;6(2):108, 113-14, 117-18, 121.
• Outcome analysis of a formulary transition from nifedipine to felodipine at a Veterans Affairs Medical Center. 1999;5(5):425-28.
• Formulary management by an on-site school of pharmacy faculty member in a Medicaid managed care organization. 1998;4(4):407-10.
• DOD's Pharmacoeconomic Center: translating research into good patient care practices. 1997;3(6):662-64, 666.
• Drug formularies: real opportunities to improve MCO efficiency. 1997;3(3):254, 375-76.
• Using outcomes as a tool to evaluate formulary selection decisions: hypercholesterolemia as a case example. 1996;2(4):396-404.

Formulary Management—P&T Committees

Health Care Delivery
• A review of the use of CAM therapy and the sources of accurate and reliable information. 2005;11(8):695-703.
• Development of a complementary and alternative medicine (CAM) pharmacy and therapeutics (P&T) subcommittee and CAM guide for providers. 2005;11(3):252-58.
• International markets offer new opportunities for MCOs and PBMs. 1997;3(4):403-04, 409-10.
• Integration takes managed care in different directions: horizontal, vertical, and beyond. 1997;3(3):260, 263-64.
• Alternative medicine in managed care pharmacy. 1997;3(1):77-80, 83-86.
• Indian Health Service: paving the way for pharmaceutical care. 1997;3(1):36, 41-43.
• While health care evolves, antitrust law endures. 1996;2(6):679-86.

Health Care Quality Improvement
• Evaluation of the relationship between a chronic disease care management program and California pay-for-performance diabetes care cholesterol measures in one medical group. 2007;13(7):578-88.
• Information technology to cross the quality chasm. 2002; 8(5):401-02.
• Quality improvement opportunities in health care—making it easy to do it right. 2002;8(5):394-99.
• Quality measures: looking in all the wrong places. 2001; 7(2):88.
• Medical and medication errors: a partial summary of reports by the Institute of Medicine and the quality interagency coordination task force. 2001;7(1):62-68.
• How to evaluate disease state management programs. 1997; 3(3):270, 273-74, 277-78.
• Managed care and the quest for quality measures. 1997; 3(3):255, 258-89.
• Successful CQI-based programs in a group-model managed care setting. 1995;1(2):134, 137.

Health Care Spending and Health Economics
• Medical costs and resource utilization for hemophilia patients with and without HIV or HCV infection. 2007;13(9):790-98.
• Is there no prescription to decrease health care outlays in the face of an aging population? 2000;6(6):450-51.
• Health economics II: some unique aspects of health economics. 2000;6(2):173-78.

Health Insurance and Health Care Finance
• Direct contracting: the next purchaser strategy. 1996; 2(1):11-12, 14, 16.

Institutional Managed Care
• Managed pharmaceutical care within a criminal justice system. 2001;7(3):182.

Internet Pharmacy
• Concern about foreign-source pharmacy Internet providers. 2001;7(5):335-36.
• The Internet and PBMs: new business model or business as usual? 2000;6(2):102, 105-07.

Lifestyle Drugs

Managed Care Pharmacy Practice
• Quality articles require peer reviewers—as well as authors. [letter] 2005;11(2):186.
• John Ogden talks about managed care in the Veterans Administration. 2002;8(2):91-93.
• Managed care and the pharmacy profession revisited. 1999; 5(2):78.
• The importance of communication skills for the managed care pharmacist. 1998;4(2):102.
• The changing face of managed care pharmacy and the role of PBMs. 1997;3(5):494, 497-98.
• Blue Cross and Blue Shield: making pharmaceutical care a key component of managed care. 1996;2(1):33-34, 36, 38.
• Professional opportunities in managed care pharmacy. 1995;1(2):80, 82, 86-87.

Managed Health Care

• Medicare PPOs and managed care. 2003;9(1):91.
• Examining the managed health care continuum. 1997;3(5):511-12, 515-16, 518.

Manpower and Job Satisfaction

• A closer look at pharmacy technicians. 2003;9(1):84.
• How many pharmacists are in our future? The Bureau of Health Professions projects supply to 2020. 2000;6(6):474-82.
• Burnout in a sample of HMO pharmacists using the Maslach Burnout Inventory. 1998;4(5):495-503.

Medicaid


Medicare and Medication Therapy Management

(see also Drug Benefit Management—Benefit Design)

• Unprecedented opportunities for managed care and community pharmacy to work together. 2007;13(5):426-28.
• Medication therapy management programs: when will the outcomes come out? [commentary] 2007;13(3):276-77.

• Characteristics of older adults who meet the annual prescription drug expenditure threshold for Medicare medication therapy management programs. 2007;13(2):142-54.
• Timeline and potential impact of CMS’s drug Competitive Acquisition Program (CAP). 2006;12(3):263-64.

Pain Management

• Beyond narcotics for effective pain management. 2003;9(2):175-76.
• It’s a pain. 1999;5(6):558.

Pharmaceutical Industry and Marketing

• Pharmaceutical patient assistance programs: don’t look a gift horse in the mouth or there’s no such thing as a free lunch. [commentary]. 2007;13(7):614-16.
Pharmacogenomics

- Health care professionals' perceptions of the role of pharmacogenomic data. 2002;8(4):278-84.

Pharmacy Education

- Managed care and the University of Texas College of Pharmacy. 2001;7(6):490.
- University of Michigan College of Pharmacy and managed care partner to enhance drug therapy. 2001;7(5):345-46.
- An inside look at the benefits of a student pharmacy and therapeutics (P&T) committee competition from the University of Illinois at Chicago. 2001;7(4):259-60.
- Managed care concepts prominently featured in innovative management programs at Duquesne University. 2001; 7(2):94, 96.
- The University of Maryland's Center on Drugs and Public Policy. 2000;6(2):184-85.
- Managed care pharmacy practice at the Texas Tech University Health Sciences Center School of Pharmacy. 1999;5(6):556-57.
- Description of a formal affiliation between a school of pharmacy and a managed care organization. 1999;5(5):433-37.
- Improving efficiency and effectiveness in managed care: ongoing efforts at the University of New Mexico College of Pharmacy. 1999;5(2):111.
- First managed care pharmacy course at the University of Illinois at Chicago. 1998;4(1):80-81.
- Pharmacy internship offers real-world exposure to managed care pharmacy practice. 1998;4(6):605-06.
- Managed care pharmacy education at the University of Washington School of Pharmacy. 1996;2(3):319-20.
Physician Education Interventions
Including Academic Detailing

• Assessment of epifibatide dosing in renal impairment before and after in-service education provided by pharmacists. 2007;13(7):598-606.
• Selection bias in physician education-intervention programs. 2002;8(2):82.
• Driving market share in an integrated health system without therapeutic interchange. 2001;7(4):283-86.
• UIC students mobilize first student chapter of AMCP. 1995;1(3):185-86.

Population Health—Interventions and Prevention of ADEs

• Suboptimal pneumococcal pneumonia vaccination rates among patients at risk in a managed care organization in Israel. 2006;12(3):152-56.

Prior Authorization (PA) (see Drug Benefit Management—Quantity Limits, Step Therapy, Prior Authorization (PA), Drug Pricing Rebates)

• Employer access to employee prescription records: dilemmas for pharmacists. 1997;3(5):504-05, 508.

Quality Assurance


Research Methods and Statistical Analysis (see also Survey Methods)

• Differentiating effective data mining from fishing, trapping, and cruelty to numbers—just right or too much of a good thing? [editorial] 2007;13(6):517-27.
• Peeking inside the statistical black box: how to analyze quantitative information and get it right the first time. [editorial] 2007;13(1):70-74.
• Conjoint analysis in pharmaceutical research. 2002;8(3):206-08.
• Researching managed care pharmacy using Internet searches. 2001;7(3):201-04, 213.
• Method is everything: evaluating results by study design. 1997;3(1):66-68, 71-72, 75-76.
• Epidemiological techniques. 1997;3(1):30-32, 35.
• Interface between pharmacoepidemiology and pharmacoconomics in managed care pharmacy. 1996;2(3):282-89.
• Outcomes research, pharmacoeconomics, and the pharmaceutical industry. 1996;2(2):48-52.
### Article Index by Subject Category

<table>
<thead>
<tr>
<th>Category</th>
<th>Articles</th>
</tr>
</thead>
<tbody>
<tr>
<td>Safety—Patient Care (see Drug Utilization Review [DUR])</td>
<td></td>
</tr>
<tr>
<td>Specialty Pharmacy</td>
<td>• Specialty pharmacy cost management strategies of private health care payers. 2006;12(9):736-44.</td>
</tr>
<tr>
<td></td>
<td>• The emergence of specialty pharmacy. 2000;6(4):280-84.</td>
</tr>
<tr>
<td>Survey Methods (see also Research Methods and Statistical Analysis)</td>
<td>• Constructing mail survey questionnaires to maximize the rates of return and assure the validity and reliability of responses. 2002;8(3):225-31.</td>
</tr>
<tr>
<td></td>
<td>• Use of technology throughout the curriculum. 2002;8(2):86.</td>
</tr>
<tr>
<td></td>
<td>• Automation aids prescription processing—but professional judgment remains indispensable. 1995;1(2):90, 93-95.</td>
</tr>
<tr>
<td>Technology—Electronic Prescribing</td>
<td>• Standardization is necessary in the methods to assess the value of electronic prescribing systems. [letter] 2005; 11(7):594-95.</td>
</tr>
<tr>
<td></td>
<td>• Extent of electronic prescribing implementation as perceived by MCO pharmacy managers. 2002;8(1):41-47.</td>
</tr>
<tr>
<td>Therapeutic Interchange—Therapeutic Selection</td>
<td>• Utilization of pharmacy claims data to evaluate therapeutic interchange programs. 1999;5(4):331-34.</td>
</tr>
<tr>
<td>Women’s Health</td>
<td>• Actuarial analysis of private payer administrative claims data for women with endometriosis. 2007;13(3):262-72.</td>
</tr>
</tbody>
</table>